Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis

Clinical and Vaccine Immunology

Volumn 22, Issue 1, 2015, Pages 91-98

  Henao Tamayo, Marcela ^a   Obregón Henao, Andrés ^a   Creissen, Elizabeth ^a   Shanley, Crystal ^a   Orme, Ian ^a   Ordway, Diane J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BCG VACCINATION; C3H/HEOUJ MOUSE; C3HEB/FE MOUSE; CONTROLLED STUDY; DRUG EFFICACY; EFFECTOR CELL; GRANULOMA; IMMUNE RESPONSE; INFECTION; MEMORY T LYMPHOCYTE; MOUSE; MOUSE STRAIN; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRAIN DIFFERENCE; TUBERCULOSIS; ANIMAL; BIOSYNTHESIS; C3H MOUSE; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; MYCOBACTERIUM BOVIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; MICE, INBRED C3H; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 84920519594     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00466-14     Document Type: Article

References (27)

1. World Health Organization. 2011. Global tuberculosis control: WHO report 2011, p viii, 122-246. World Health Organization, Geneva, Switzerland.
2. North RJ, Jung YJ. 2004.Immunityto tuberculosis.AnnuRevImmunol22: 599-623. http://dx.doi.org/10.1146/annurev.immunol.22.012703.104635.
3. Pitt JM, Blankley S, McShane H, O'Garra A. 2013. Vaccination against tuberculosis: how can we better BCG? Microb Pathog 58: 2-16. http://dx.doi.org/10.1016/j.micpath.2012.12.002.
4. Fine PE. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345. http://dx.doi.org/10.1016/S0140-6736(95)92348-9.
5. Orme IM. 2006. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24: 2-19. http://dx.doi.org/10.1016/j.vaccine.2005.07.078.
6. Basaraba RJ. 2008. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb) 88: S35-S47. http://dx.doi.org/10.1016/S1472-9792 (08)70035-0.
7. Kramnik I, Dietrich WF, Demant P, Bloom BR. 2000. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 97: 8560-8565. http://dx.doi.org/10.1073/pnas.150227197.
8. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434: 767-772. http://dx.doi.org/10.1038/nature03419.
9. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205: 595-602. http://dx.doi.org/10.1093/infdis/jir786.
10. + myeloid-derived suppressor cells in Mycobacterium tuberculosis infection.PLoSOne8: e80669. http://dx.doi.org/10.1371/journal.pone.0080669.
11. Junqueira-Kipnis AP, Turner J, Gonzalez-Juarrero M, Turner OC, Orme IM. 2004. Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun 72: 570-575. http://dx.doi.org/10.1128/IAI.72.1.570-575.2004.
12. Ordway DJ, Shang S, Henao-Tamayo M, Obregon-Henao A, Nold L, Caraway M, Shanley CA, Basaraba RJ, Duncan CG, Orme IM. 2011. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol 18: 1527-1535. http://dx.doi.org/10.1128/CVI.05127-11.
13. Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, Shanley C, Basaraba RJ, Orme IM. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 179: 522-531. http://dx.doi.org/10.4049/jimmunol.179.1.522.
14. Ordway D, Henao-Tamayo M, Shanley C, Smith EE, Palanisamy G, Wang B, Basaraba RJ, Orme IM. 2008. Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin Vaccine Immunol 15: 1248-1258. http://dx.doi.org/10.1128/CVI.00019-08.
15. Yan BS, Pichugin AV, Jobe O, Helming L, Eruslanov EB, Gutiérrez-Pabello JA, Rojas M, Shebzukhov YV, Kobzik L, Kramnik I. 2007. Progression of pulmonary tuberculosis and efficiency of bacillus Calmette-Guerin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity. J Immunol 179: 6919-6932. http://dx.doi.org/10.4049/jimmunol.179.10.6919.
16. Orme IM. 2011. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol 6: 161-177. http://dx.doi.org/10.2217/fmb.10.168.
17. Orme IM. 2010. The Achilles heel of BCG. Tuberculosis (Edinb) 90: 329-332. http://dx.doi.org/10.1016/j.tube.2010.06.002.
18. Andersen P, Doherty TM. 2005. The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662. http://dx.doi.org/10.1038/nrmicro1211.
19. Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. 2012. Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases. J Infect 64: 543-554. http://dx.doi.org/10.1016/j.jinf.2012.03.012.
20. Henao-Tamayo M, Obregón-Henao A, Ordway DJ, Shang S, Duncan CG, Orme IM. 2012. A mouse model of tuberculosis reinfection. Tuberculosis (Edinb) 92: 211-217. http://dx.doi.org/10.1016/j.tube.2012.02.008.
21. Irwin SM, Goodyear A, Keyser A, Christensen R, Troudt JM, Taylor JL, Bohsali A, Briken V, Izzo AA. 2008. Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model. Clin Vaccine Immunol 15: 750-756. http://dx.doi.org/10.1128/CVI.00018-08.
22. Minassian AM, Ronan EO, Poyntz H, Hill AV, McShane H. 2011. Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. PLoS One 6: e19840. http://dx.doi.org/10.1371/journal.pone.0019840.
23. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol 174: 2190-2201. http://dx.doi.org/10.2353/ajpath.2009.081075.
24. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, Tsenova L, Kaplan G, Russell DG. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2: 258-274. http://dx.doi.org/10.1002/emmm.201000079.
25. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry CE, III, Stoeckli M. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83: 2112-2118. http://dx.doi.org/10.1021/ac1029049.
26. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. 2009. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10: 943-948. http://dx.doi.org/10.1038/ni.1781.
27. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977. http://dx.doi.org/10.1038/nature09247.